Proficiency testing programs for Alzheimers disease cerebrospinal fluid biomarkers

Biomarkers in Medicine

Volumn 6, Issue 4, 2012, Pages 401-407

  Mattsson, Niklas ^a   Andreasson, Ulf ^a   Carrillo, Maria C ^b   Persson, Staffan ^a   Shaw, Leslie M ^c   Zegers, Ingrid ^d   Zetterberg, Henrik ^a,e   Blennow, Kaj ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ALZHEIMER'S ASSOCIATION   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d JOINT RESEARCH CENTRE   (Italy)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimers disease; biomarkers; cerebrospinal fluid; proficiency testing

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; ANALYTICAL EQUIPMENT; CEREBROSPINAL FLUID ANALYSIS; CONSENSUS DEVELOPMENT; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GOOD LABORATORY PRACTICE; HUMAN; LABORATORY TEST; MEDICAL EDUCATION; MOLECULAR STABILITY; NERVE FIBER DEGENERATION; NEUROCHEMISTRY; NEUROFIBRILLARY TANGLE; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; QUALITY CONTROL; REFERENCE VALUE; RELIABILITY; REVIEW; STANDARDIZATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; HUMANS; LABORATORY PROFICIENCY TESTING; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 84865507286     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.41     Document Type: Review

References (25)

1. Mattsson N. Review: CSF biomarkers in neurodegenerative diseases. Clin. Chem. Lab. Med. 49(3), 345-352 (2011).
2. Albert MS, Dekosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7(3), 270-279 (2011).
3. Dubois B, Feldman HH, Jacova C et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 9(11), 1118-1127 (2010).
4. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7(3), 263-269 (2011).
5. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2(10), 605-613 (2003). (Pubitemid 37162569)
6. Mattsson N, Andreasson U, Persson S et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 7(4), 386-395 e6 (2011). □□ Describes an ongoing global proficiency testing program for cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers.
7. Olsson A, Vanderstichele H, Andreasen N et al. Simultaneous measurement of beta-amyloid (1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 51(2), 336-345 (2005). (Pubitemid 40175803)
8. Reijn TS, Rikkert MO, Van Geel WJ, De Jong D, Verbeek MM. Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta (42) and tau proteins. Clin. Chem. 53(5), 859-865 (2007). (Pubitemid 46744241)
9. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5(3), 228-234 (2006). (Pubitemid 43238346)
10. Johansson P, Mattsson N, Hansson O et al. cerebrospinal fluid biomarkers for alzheimer's disease: diagnostic performance in a homogeneous mono-center population. J. Alzheimers Dis. 24(3), 537-546 (2011).
11. Mattsson N, Blennow K, Zetterberg H. Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clin. Chem. Lab. Med. 48(5), 603-607 (2010).
12. Schoonenboom NS, Mulder C, Vanderstichele H et al. Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin. Chem. 51(1), 189-195 (2005). (Pubitemid 40024030)
13. Lewczuk P, Beck G, Esselmann H et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin. Chem. 52(2), 332-334 (2006). (Pubitemid 43185505)
14. Bjerke M, Portelius E, Minthon L et al. Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int. J. Alzheimers Dis. 21(1), 221-228 (2010).
15. Vanderstichele H, Bibl M, Engelborghs S et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement. 8(1), 65-73 (2012). □ Proposal to standardize preanalytical factors influencing CSF AD biomarker measurements.
16. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6(3), 131-144 (2010).
17. Mattsson N, Zegers I, Andreasson U et al. Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers - definitions and approaches with focus on amyloid b42. Biomarkers Med. 6 (4) 409-417 (2012)
18. Belk WP, Sunderman FW. A survey of the accuracy of chemical analyses in clinical laboratories. Am. J. Clin. Pathol. 17(11), 853-861 (1947).
19. Miller WG, Jones GR, Horowitz GL, Weykamp C. Proficiency testing/external quality assessment: current challenges and future directions. Clin. Chem. 57(12), 1670-1680 (2011).
20. Zimmermann R, Lelental N, Ganslandt O, Maler JM, Kornhuber J, Lewczuk P. Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics. J. Alzheimers Dis. 25(4), 739-745 (2011).
21. Miller WG, Myers GL, Rej R. Why commutability matters. Clin. Chem. 52(4), 553-554 (2006).
22. Witte DL. Medically relevant laboratoryperformance goals: a listing of the complexities and a call for action. Clin. Chem. 39(7), 1530-1535 (1993). (Pubitemid 23215345)
23. Lewczuk P, Beck G, Ganslandt O et al. International quality control survey of neurochemical dementia diagnostics. Neurosci. Lett. 409(1), 1-4 (2006). (Pubitemid 44740057)
24. Verwey NA, Van der Flier WM, Blennow K et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann. Clin. Biochem. 46(Pt 3), 235-240 (2009).
25. Shaw LM, Vanderstichele H, Knapik-Czajka M et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 121(5), 597-609 (2011).